Two preclinical studies also found that recombinant thrombomodulin could prevent peripheral neuropathy induced by bortezomib and paclitaxel in rats and mice (Miyamoto et al., 2021; Tsubota et al., 2021). Here, THBD is linked to peripheral neuropathy.